Table 1. Demographics and clinical characteristics of patients with COVID-19.
| Characteristic | No. (%) | ||||
|---|---|---|---|---|---|
| Total (n = 564) | Non-diabetes (n = 479) | Diabetes (n = 85) | P value | ||
| Age-median(range) | 59 (10-93) | 57 (10-93) | 65 (34-91) | <0.0001 | |
| Sex | |||||
| Female | 289 (51.2) | 253 (52.8) | 36 (42.4) | 0.0786 | |
| Male | 275 (48.8) | 226 (47.2) | 49 (57.6) | ||
| Smoking | 42 (7.4) | 38 | 4 | 0.3745 | |
| Onset of symptom to hospital admission, median (IQR), d | 10 (6-15) | 10 (6-15) | 10 (7-15) | 0.7271 | |
| Hospitalization, median (IQR), d | 15 (9-24) | 15 (9-23) | 17 (10-25) | 0.3302 | |
| Comorbidity – No. (%) | |||||
| Cardiovascular disease | 70 (12.4) | 45 (9.4) | 25 (29.4) | <0.0001 | |
| Cerebrovascular disease | 11 (2.0) | 7 (1.5) | 4 (4.7) | 0.0685 | |
| Hypertension | 190 (33.7) | 132 (27.6) | 58 (68.2) | <0.0001 | |
| Chronic bronchitis | 12 (2.1) | 11 (2.3) | 1 (1.2) | 1 | |
| Malignancy | 24 (4.3) | 18 (3.8) | 6 (7.1) | 0.2364 | |
| Liver disease | 33 (5.9) | 29 (6.1) | 4 (4.7) | 0.8038 | |
| Kidney disease | 25 (4.4) | 19 (4.0) | 6 (7.1) | 0.2461 | |
| Allergic physique | 19 (3.4) | 15 (3.1) | 4 (4.7) | 0.5092 | |
| Complication | |||||
| Bacterial infection | 42 (7.4) | 35 (7.3) | 7 (8.2) | 0.8220 | |
| Metabolic acidosis | 19 (3.4) | 11 (2.3) | 8 (9.4) | 0.0036 | |
| Heart failure | 25 (4.4) | 15 (3.1) | 10 (11.8) | 0.0017 | |
| ARDS | 61 (10.8) | 41 (8.6) | 20 (23.5) | 0.0002 | |
| Acute liver injury | 24 (4.3) | 18 (3.8) | 6 (7.1) | 0.2364 | |
| Acute kidney injury | 27 (4.8) | 19 (4.0) | 8 (9.4) | 0.0477 | |
| DIC | 7 (1.2) | 3 (0.6) | 4 (4.7) | 0.0118 | |
| Treatments | |||||
| Antiviral treatment | 351 (62.2) | 299 (62.4) | 52 (61.2) | 0.9034 | |
| Antibiotics | 407(72.1) | 341 (71.1) | 66 (77.6) | 0.2397 | |
| Chinese Medicine | 343 (60.8) | 289 (60.3) | 54 (63.5) | 0.6305 | |
| Glucocorticoid | 193 (34.2) | 159 (33.2) | 34 (40.0) | 0.2641 | |
| Immune globulin | 90 (16.0) | 70 (14.6) | 20 (23.5) | 0.0524 | |
| Respiratory support | 0.0462 | ||||
| Nasal cannula | 305 (54.1) | 257 (53.7) | 48 (56.5) | ||
| Non-invasive ventilation | 35 (6.2) | 25 (5.2) | 10 (11.8) | ||
| Invasive ventilation | 15 (2.7) | 10 (2.1) | 5 (5.9) | ||
| Diseases severity | 0.0018 | ||||
| Moderate | 284 (50.4) | 252 (52.6) | 32 (37.6) | ||
| Severe | 190 (33.7) | 161 (33.6) | 29 (34.1) | ||
| Critical | 90 (16.0) | 66 (13.8) | 24 (28.2) | ||
| Clinical outcomes | 0.0022 | ||||
| Discharge | 509 (90.2) | 441 (92.1) | 68 (80.0) | ||
| Death | 55 (9.8) | 38 (7.9) | 17 (20.0) | ||
ARDS: acute respiratory distress syndrome; DIC: disseminated intravascular coagulation; IQR: interquartile range.